TRAVERE THERAPEUTICSCS INC
Acción · US89422G1076 · TVTX · A2QHYP (XNAS)
15,32 USD
06.06.2025 20:00
Cotizaciones actuales de TRAVERE THERAPEUTICSCS INC
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
TVTX
|
USD
|
06.06.2025 20:00
|
15,32 USD
| 14,72 USD
+4,08 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | 2,00 % | -23,21 % | -19,11 % | -20,29 % | 111,89 % | -5,84 % |
Perfil de la empresa para TRAVERE THERAPEUTICSCS INC Acción
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fondos invertidos
Los siguientes fondos han invertido en: TRAVERE THERAPEUTICSCS INC invertido:
Fondo | Vol. en millones 43,83 | Porcentaje (%) 0,10 % |
Datos de la empresa
Nombre TRAVERE THERAPEUTICSCS INC
Empresa Travere Therapeutics, Inc.
Símbolo TVTX
Sitio web
https://www.travere.com
Mercado principal
NASDAQ

WKN A2QHYP
ISIN US89422G1076
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Eric M. Dube Ph.D.
Capitalización de mercado 1 Mrd.
País Estados Unidos de América
Moneda USD
Empleados 0,4 T
Dirección 3611 Valley Centre Drive, 92130 San Diego
Fecha de OPV 2012-11-08
Cambios de identificador
Fecha | De | A |
---|---|---|
19.11.2020 | RTRX | TVTX |
Símbolos de cotización
Nombre | Símbolo |
---|---|
NASDAQ | TVTX |
Otras acciones
Los inversores que tienen TRAVERE THERAPEUTICSCS INC también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.